Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: A universally available prognostic test

被引:34
作者
Nowakowski, Grzegorz S.
Hoyer, James D.
Shanafelt, Tait D.
Geyer, Susan M.
LaPlant, Betsy R.
Call, Timothy G.
Jelinek, Diane F.
Zent, Clive S.
Kay, Neil E.
机构
[1] Mayo Clin & Mayo Fdn, Med Ctr, Div Hematol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Med Ctr, Div Hematopathol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Med Ctr, Canc Ctr Stat, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Med Ctr, Dept Immunol, Rochester, MN 55905 USA
关键词
D O I
10.4065/82.4.449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently developed prognostic tests in early Rai and Binet stage chronic lymphocytic leukemia (CLL) require considerable technGlogic expertise and are not available worldwide. Smudge cells are CLL cells ruptured during smear preparation. We hypothesized that smudge cell formation is inversely correlated with expression of vimentin, a cytoskeletal protein and prognostic marker, and that the percentage of smudge cells would predict prognosis in CLL. We reviewed the blood smears of 75 patients with previously untreated early- and intermediate-stage CLL (Rai stage 0-II) who were seen at the Mayo Clinic in Rochester, Minn, between September 1989 and December 2000. A total of 200 lymphocytes and smudge cells were counted on each slide and the results expressed as a percentage of the total lymphocytes (intact and smudged). The median percentage of smudge cells was 27% (range, 40/72%). The percentage of smudge cells inversely correlated with vimentin expression (r=-0.57; P=-.007). The median percentage of smudge cells was higher in patients with the mutated immunoglobulin heavy chain gene than in those with the unmutated immunoglobulin heavy chain gene (31% vs 13%; P=-.02). Patients with less than 30% smudge cells had a median time from diagnosis to initial treatment of 72.7 months, whereas the median time from diagnosis to initial treatment in patients with 30% or more smudge cells was not reached (P=-.001). The percentage of smudge cells as a continuous variable correlated with overall survival (P=-.04). The estimation of smudge cells on a blood smear could be a universally available prognostic test in early-stage CLL.
引用
收藏
页码:449 / 453
页数:5
相关论文
共 25 条
[1]  
BINET JL, 1993, BLOOD CELLS, V19, P573
[2]   Rigidity of circulating lymphocytes is primarily conferred by vimentin intermediate filaments [J].
Brown, MJ ;
Hallam, JA ;
Colucci-Guyon, E ;
Shaw, S .
JOURNAL OF IMMUNOLOGY, 2001, 166 (11) :6640-6646
[3]   INCIDENCE OF CHRONIC LYMPHOCYTIC-LEUKEMIA IN OLMSTED COUNTY, MINNESOTA, 1935 THROUGH 1989, WITH EMPHASIS ON CHANGES IN INITIAL-STAGE AT DIAGNOSIS [J].
CALL, TG ;
PHYLIKY, RL ;
NOEL, P ;
HABERMANN, TM ;
BEARD, CM ;
OFALLON, WM ;
KURLAND, LT .
MAYO CLINIC PROCEEDINGS, 1994, 69 (04) :323-328
[4]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[5]   Mechanisms of disease: Chronic lymphocytic leukemia [J].
Chiorazzi, N ;
Rai, KR ;
Ferrarini, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :804-815
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia [J].
Crespo, M ;
Bosch, F ;
Villamor, N ;
Bellosillo, B ;
Colomer, D ;
Rozman, M ;
Marcé, S ;
López-Guillermo, A ;
Campo, E ;
Montserrat, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1764-1775
[8]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847
[9]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916
[10]  
Gumprecht F., 1896, DEUT ARCH KLIN MED, V57, P523